Free Trial

Global Medical REIT (GMRE) Financials

Global Medical REIT logo
$6.16 +0.01 (+0.08%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Annual Income Statements for Global Medical REIT

Annual Income Statements for Global Medical REIT

This table shows Global Medical REIT's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders
0.81 15 13
Consolidated Net Income / (Loss)
6.69 22 20
Net Income / (Loss) Continuing Operations
4.20 7.04 13
Total Pre-Tax Income
4.20 7.04 13
Total Revenue
110 110 112
Net Interest Income / (Expense)
-29 -31 -25
Total Interest Income
0.00 0.00 0.00
Total Interest Expense
29 31 25
Long-Term Debt Interest Expense
29 31 25
Total Non-Interest Income
139 141 137
Other Service Charges
0.37 0.12 0.12
Other Non-Interest Income
138 141 137
Total Non-Interest Expense
106 103 99
Other Operating Expenses
50 45 42
Depreciation Expense
40 41 40
Amortization Expense
15 17 17
Restructuring Charge
0.16 0.04 0.35
Other Gains / (Losses), net
-1.72 -0.87 0.00
Net Income / (Loss) Discontinued Operations
4.21 16 6.75
Preferred Stock Dividends Declared
5.82 5.82 5.82
Net Income / (Loss) Attributable to Noncontrolling Interest
0.06 1.12 0.85
Basic Earnings per Share
$0.01 $0.23 $0.20
Weighted Average Basic Shares Outstanding
65.94M 65.55M 65.46M
Diluted Earnings per Share
$0.01 $0.23 $0.20
Weighted Average Diluted Shares Outstanding
65.94M 65.55M 65.46M
Weighted Average Basic & Diluted Shares Outstanding
66.87M 65.57M 65.53M
Cash Dividends to Common per Share
$0.84 $0.84 $0.84

Quarterly Income Statements for Global Medical REIT

This table shows Global Medical REIT's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
1.37 1.79 -3.15 0.79 -0.84 3.14 12 0.67 0.37 8.06
Consolidated Net Income / (Loss)
2.94 3.39 -1.95 2.31 0.55 4.83 14 2.17 1.85 10
Net Income / (Loss) Continuing Operations
-1.11 1.57 1.43 2.31 1.42 2.54 1.39 1.69 1.85 3.28
Total Pre-Tax Income
-1.11 1.57 1.43 2.31 1.42 2.54 1.39 1.69 1.85 3.28
Total Revenue
28 27 27 28 26 28 28 28 28 28
Net Interest Income / (Expense)
-7.57 -7.24 -6.99 -6.89 -6.98 -7.17 -8.47 -8.27 -8.07 -6.96
Total Interest Expense
7.57 7.24 6.99 6.89 6.98 7.17 8.47 8.27 8.07 6.96
Long-Term Debt Interest Expense
7.57 7.24 6.99 6.89 6.98 7.17 8.47 8.27 8.07 6.96
Total Non-Interest Income
35 34 34 35 33 36 36 36 36 35
Other Service Charges
0.21 0.09 0.03 0.05 0.03 0.02 0.03 0.03 0.02 0.06
Other Non-Interest Income
35 34 34 35 33 35 36 36 36 35
Total Non-Interest Expense
29 25 26 26 25 26 26 26 26 25
Other Operating Expenses
15 12 12 12 10 12 12 11 11 11
Depreciation Expense
10 9.99 10 10 10 10 10 10 11 10
Amortization Expense
3.45 3.65 3.87 3.97 4.04 4.10 4.34 4.40 4.51 4.29
Restructuring Charge
0.16 0.00 0.00 0.00 - 0.00 0.00 0.04 0.11 0.11
Net Income / (Loss) Discontinued Operations
5.77 1.82 -3.38 0.00 - 2.29 13 0.49 - 6.75
Preferred Stock Dividends Declared
1.46 1.46 1.46 1.46 1.46 1.46 1.46 1.46 1.46 1.46
Net Income / (Loss) Attributable to Noncontrolling Interest
0.11 0.15 -0.26 0.07 -0.07 0.24 0.90 0.05 0.02 0.52
Basic Earnings per Share
$0.02 $0.03 ($0.05) $0.01 ($0.01) $0.05 $0.18 $0.01 $0.01 $0.12
Weighted Average Basic Shares Outstanding
65.94M 65.74M 65.59M 65.57M 65.55M 65.57M 65.54M 65.53M 65.46M 65.52M
Diluted Earnings per Share
$0.02 $0.03 ($0.05) $0.01 ($0.01) $0.05 $0.18 $0.01 $0.01 $0.12
Weighted Average Diluted Shares Outstanding
65.94M 65.74M 65.59M 65.57M 65.55M 65.57M 65.54M 65.53M 65.46M 65.52M
Weighted Average Basic & Diluted Shares Outstanding
66.87M 66.80M 65.59M 65.59M 65.57M 65.56M 65.56M 65.53M 65.53M 65.52M

Annual Cash Flow Statements for Global Medical REIT

This table details how cash moves in and out of Global Medical REIT's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents
2.22 -7.73 1.70
Net Cash From Operating Activities
70 68 77
Net Cash From Continuing Operating Activities
70 68 77
Net Income / (Loss) Continuing Operations
6.69 22 20
Consolidated Net Income / (Loss)
6.69 22 20
Depreciation Expense
40 41 40
Amortization Expense
18 20 20
Non-Cash Adjustments to Reconcile Net Income
2.99 -8.99 -1.58
Changes in Operating Assets and Liabilities, net
2.04 -5.69 -1.74
Net Cash From Investing Activities
-46 68 -137
Net Cash From Continuing Investing Activities
-46 68 -137
Purchase of Investment Securities
-103 -11 -156
Sale and/or Maturity of Investments
57 79 18
Other Investing Activities, net
0.00 0.00 1.00
Net Cash From Financing Activities
-22 -144 62
Net Cash From Continuing Financing Activities
-22 -144 62
Net Change in Deposits
0.25 7.16 -1.97
Issuance of Debt
144 83 139
Issuance of Common Equity
11 0.00 9.90
Repayment of Debt
-111 -169 -20
Payment of Dividends
-66 -65 -64
Cash Interest Paid
27 30 22

Quarterly Cash Flow Statements for Global Medical REIT

This table details how cash moves in and out of Global Medical REIT's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
1.15 -0.03 0.01 1.08 -0.89 -2.17 -4.20 -0.47 0.86 -0.61
Net Cash From Operating Activities
21 16 19 14 18 17 18 16 18 18
Net Cash From Continuing Operating Activities
21 16 19 14 18 17 18 16 18 18
Net Income / (Loss) Continuing Operations
2.94 3.39 -1.95 2.31 0.55 4.83 14 2.17 1.85 10
Consolidated Net Income / (Loss)
2.94 3.39 -1.95 2.31 0.55 4.83 14 2.17 1.85 10
Depreciation Expense
10 9.99 10 10 10 10 10 10 11 10
Amortization Expense
4.26 4.39 4.58 4.68 4.79 4.87 5.19 5.27 5.38 5.06
Non-Cash Adjustments to Reconcile Net Income
-3.44 -0.61 5.61 1.44 3.11 -0.86 -11 0.22 1.15 -5.54
Changes in Operating Assets and Liabilities, net
6.57 -0.86 0.57 -4.25 -0.54 -2.27 -0.50 -2.38 -0.65 -1.36
Net Cash From Investing Activities
-20 -25 1.79 -2.72 -3.11 5.66 62 3.09 -1.41 -33
Net Cash From Continuing Investing Activities
-20 -25 1.79 -2.72 -3.11 5.66 62 3.09 -1.41 -33
Purchase of Investment Securities
-59 -36 -5.21 -2.55 -4.11 -3.86 -2.53 -0.81 -1.89 -53
Sale and/or Maturity of Investments
38 12 7.49 -0.17 1.00 9.53 64 4.05 0.17 18
Other Investing Activities, net
1.25 -0.75 -0.50 0.00 - - 0.15 -0.15 0.30 1.49
Net Cash From Financing Activities
0.15 9.16 -21 -10 -16 -25 -84 -19 -16 15
Net Cash From Continuing Financing Activities
0.15 9.16 -21 -10 -16 -25 -84 -19 -16 15
Net Change in Deposits
0.02 -0.02 0.31 -0.06 8.20 -0.14 -0.26 -0.64 -0.57 -0.44
Issuance of Debt
61 44 25 14 45 14 12 13 12 35
Repayment of Debt
-44 -30 -29 -8.03 -53 -22 -80 -15 -11 -3.53
Payment of Dividends
-17 -16 -16 -16 -16 -16 -16 -16 -16 -16
Cash Interest Paid
7.05 6.94 6.18 6.41 6.86 7.00 8.15 8.14 6.37 6.21

Annual Balance Sheets for Global Medical REIT

This table presents Global Medical REIT's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets
1,256 1,268 1,393
Cash and Due from Banks
6.82 1.28 4.02
Restricted Cash
2.13 5.45 10
Interest Bearing Deposits at Other Banks
0.71 0.67 7.83
Trading Account Securities
19 25 35
Loans and Leases, Net of Allowance
0.00 0.00 0.00
Premises and Equipment, Net
953 974 1,072
Deferred Acquisition Cost
28 27 30
Goodwill
5.90 5.90 5.90
Intangible Assets
139 139 148
Other Assets
102 89 81
Total Liabilities & Shareholders' Equity
1,256 1,268 1,393
Total Liabilities
701 662 744
Non-Interest Bearing Deposits
3.32 3.69 5.46
Short-Term Debt
632 585 636
Other Short-Term Payables
33 29 30
Long-Term Debt
14 26 58
Other Long-Term Liabilities
18 18 15
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
556 606 649
Total Preferred & Common Equity
534 584 633
Preferred Stock
75 75 75
Total Common Equity
459 509 558
Common Stock
734 722 722
Retained Earnings
-294 -239 -199
Accumulated Other Comprehensive Income / (Loss)
19 25 35
Noncontrolling Interest
22 22 16

Quarterly Balance Sheets for Global Medical REIT

This table presents Global Medical REIT's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
1,243 1,241 1,264 1,303 1,321 1,369 1,407
Cash and Due from Banks
5.72 4.98 1.33 1.28 2.46 4.60 3.20
Restricted Cash
2.07 2.84 6.47 6.33 7.33 9.38 10
Interest Bearing Deposits at Other Banks
1.69 0.93 0.74 9.86 9.73 8.63 7.66
Trading Account Securities
15 28 29 38 36 27 37
Loans and Leases, Net of Allowance
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net
948 941 960 988 1,007 1,053 1,087
Deferred Acquisition Cost
28 28 28 27 26 30 29
Goodwill
5.90 5.90 5.90 5.90 5.90 5.90 5.90
Intangible Assets
138 136 139 139 140 148 148
Other Assets
98 93 93 87 86 81 78
Total Liabilities & Shareholders' Equity
1,243 1,241 1,264 1,303 1,321 1,369 1,407
Total Liabilities
678 663 666 669 679 741 742
Non-Interest Bearing Deposits
3.22 3.97 4.38 3.91 4.21 4.69 5.40
Short-Term Debt
614 599 592 561 568 635 635
Other Short-Term Payables
30 28 27 29 32 28 29
Long-Term Debt
14 15 26 57 57 57 58
Other Long-Term Liabilities
16 17 18 18 19 15 15
Total Equity & Noncontrolling Interests
565 578 597 634 641 628 665
Total Preferred & Common Equity
543 556 575 611 620 613 649
Preferred Stock
75 75 75 75 75 75 75
Total Common Equity
468 481 500 536 545 538 574
Common Stock
734 723 723 722 722 722 722
Retained Earnings
-281 -269 -252 -224 -214 -212 -185
Accumulated Other Comprehensive Income / (Loss)
15 28 29 38 36 27 37
Noncontrolling Interest
22 22 22 22 22 16 16

Annual Metrics And Ratios for Global Medical REIT

This table displays calculated financial ratios and metrics derived from Global Medical REIT's official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics
- - -
Revenue Growth
-0.06% -1.69% 16.43%
EBITDA Growth
-8.62% -6.40% 9.83%
EBIT Growth
-40.32% -46.82% -23.33%
NOPAT Growth
-40.32% -46.82% -23.33%
Net Income Growth
-69.21% 8.69% 9.02%
EPS Growth
-95.65% 15.00% 5.26%
Operating Cash Flow Growth
2.35% -10.58% 10.98%
Free Cash Flow Firm Growth
-85.58% 218.02% 17.87%
Invested Capital Growth
-1.23% -9.39% 10.36%
Revenue Q/Q Growth
1.48% -2.01% 7.41%
EBITDA Q/Q Growth
-4.68% -2.00% 7.45%
EBIT Q/Q Growth
-37.57% -5.73% 22.69%
NOPAT Q/Q Growth
-37.57% -5.73% -16.26%
Net Income Q/Q Growth
55.48% -5.63% -15.40%
EPS Q/Q Growth
150.00% -8.00% -20.00%
Operating Cash Flow Q/Q Growth
3.54% -0.27% 1.36%
Free Cash Flow Firm Q/Q Growth
-70.23% 17.22% 28.01%
Invested Capital Q/Q Growth
0.72% -2.73% -1.05%
Profitability Metrics
- - -
EBITDA Margin
56.80% 62.12% 65.24%
EBIT Margin
3.82% 6.39% 11.82%
Profit (Net Income) Margin
6.08% 19.73% 17.85%
Tax Burden Percent
159.22% 308.63% 150.99%
Interest Burden Percent
100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.35% 0.55% 1.03%
ROIC Less NNEP Spread (ROIC-NNEP)
0.74% 2.80% 2.09%
Return on Net Nonoperating Assets (RNNOA)
0.80% 2.91% 2.07%
Return on Equity (ROE)
1.15% 3.46% 3.11%
Cash Return on Invested Capital (CROIC)
1.59% 10.40% -8.82%
Operating Return on Assets (OROA)
0.33% 0.53% 1.00%
Return on Assets (ROA)
0.53% 1.63% 1.51%
Return on Common Equity (ROCE)
0.96% 2.94% 2.67%
Return on Equity Simple (ROE_SIMPLE)
1.25% 3.72% 3.16%
Net Operating Profit after Tax (NOPAT)
4.20 7.04 13
NOPAT Margin
3.82% 6.39% 11.82%
Net Nonoperating Expense Percent (NNEP)
-0.40% -2.25% -1.06%
SG&A Expenses to Revenue
0.00% 0.00% 0.00%
Operating Expenses to Revenue
96.18% 93.61% 88.18%
Earnings before Interest and Taxes (EBIT)
4.20 7.04 13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
63 68 73
Valuation Ratios
- - -
Price to Book Value (P/BV)
1.12 1.30 0.93
Price to Tangible Book Value (P/TBV)
1.64 1.82 1.28
Price to Revenue (P/Rev)
4.68 6.01 4.62
Price to Earnings (P/E)
635.91 44.77 38.84
Dividend Yield
10.88% 8.32% 10.64%
Earnings Yield
0.16% 2.23% 2.57%
Enterprise Value to Invested Capital (EV/IC)
1.04 1.12 0.95
Enterprise Value to Revenue (EV/Rev)
11.34 12.38 11.43
Enterprise Value to EBITDA (EV/EBITDA)
19.97 19.92 17.51
Enterprise Value to EBIT (EV/EBIT)
297.16 193.58 96.67
Enterprise Value to NOPAT (EV/NOPAT)
297.16 193.58 96.67
Enterprise Value to Operating Cash Flow (EV/OCF)
17.83 19.92 16.73
Enterprise Value to Free Cash Flow (EV/FCFF)
65.04 10.24 0.00
Leverage & Solvency
- - -
Debt to Equity
1.16 1.01 1.07
Long-Term Debt to Equity
0.03 0.04 0.09
Financial Leverage
1.08 1.04 0.99
Leverage Ratio
2.17 2.12 2.06
Compound Leverage Factor
2.17 2.12 2.06
Debt to Total Capital
53.75% 50.22% 51.68%
Short-Term Debt to Total Capital
52.55% 48.09% 47.38%
Long-Term Debt to Total Capital
1.20% 2.13% 4.29%
Preferred Equity to Total Capital
6.24% 6.16% 5.58%
Noncontrolling Interests to Total Capital
1.81% 1.83% 1.20%
Common Equity to Total Capital
38.20% 41.79% 41.54%
Debt to EBITDA
10.33 8.93 9.49
Net Debt to EBITDA
10.18 8.82 9.19
Long-Term Debt to EBITDA
0.23 0.38 0.79
Debt to NOPAT
153.73 86.80 52.41
Net Debt to NOPAT
151.43 85.75 50.73
Long-Term Debt to NOPAT
3.43 3.68 4.35
Noncontrolling Interest Sharing Ratio
16.69% 15.00% 14.05%
Liquidity Ratios
- - -
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
19 133 -113
Operating Cash Flow to CapEx
0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.67 4.31 -4.47
Operating Cash Flow to Interest Expense
2.44 2.22 3.03
Operating Cash Flow Less CapEx to Interest Expense
2.44 2.22 3.03
Efficiency Ratios
- - -
Asset Turnover
0.09 0.08 0.08
Fixed Asset Turnover
0.11 0.11 0.11
Capital & Investment Metrics
- - -
Invested Capital
1,202 1,217 1,343
Invested Capital Turnover
0.09 0.09 0.09
Increase / (Decrease) in Invested Capital
-15 -126 126
Enterprise Value (EV)
1,249 1,363 1,280
Market Capitalization
516 662 517
Book Value per Share
$6.87 $7.76 $8.52
Tangible Book Value per Share
$4.71 $5.55 $6.17
Total Capital
1,202 1,217 1,343
Total Debt
646 611 694
Total Long-Term Debt
14 26 58
Net Debt
636 604 672
Capital Expenditures (CapEx)
0.00 0.00 0.00
Net Nonoperating Expense (NNE)
-2.49 -15 -6.75
Net Nonoperating Obligations (NNO)
646 611 694
Total Depreciation and Amortization (D&A)
58 61 60
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
$0.01 $0.23 $0.20
Adjusted Weighted Average Basic Shares Outstanding
65.94M 65.55M 65.46M
Adjusted Diluted Earnings per Share
$0.01 $0.23 $0.20
Adjusted Weighted Average Diluted Shares Outstanding
65.94M 65.55M 65.46M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
66.87M 65.57M 65.53M
Normalized Net Operating Profit after Tax (NOPAT)
3.05 4.96 9.52
Normalized NOPAT Margin
2.77% 4.50% 8.49%
Pre Tax Income Margin
3.82% 6.39% 11.82%
Debt Service Ratios
- - -
EBIT to Interest Expense
0.15 0.23 0.52
NOPAT to Interest Expense
0.15 0.23 0.52
EBIT Less CapEx to Interest Expense
0.15 0.23 0.52
NOPAT Less CapEx to Interest Expense
0.15 0.23 0.52
Payout Ratios
- - -
Dividend Payout Ratio
981.62% 298.37% 321.27%
Augmented Payout Ratio
981.62% 298.37% 321.27%

Quarterly Metrics And Ratios for Global Medical REIT

This table displays calculated financial ratios and metrics derived from Global Medical REIT's official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - -
Revenue Growth
6.19% -4.62% -2.27% 0.96% -8.01% -0.37% -1.46% 3.27% 37.66% 13.08%
EBITDA Growth
-18.72% -8.93% -5.38% -1.97% -7.83% -5.15% -8.70% -3.91% 39.75% 2.57%
EBIT Growth
-178.22% -38.36% 2.88% 37.09% -23.17% -22.34% -63.72% -60.62% 406.81% -38.97%
NOPAT Growth
-154.76% -38.36% 2.88% 37.09% -23.17% -22.34% -63.72% -60.62% -58.19% -38.97%
Net Income Growth
433.39% -29.84% -113.77% 6.49% -70.17% -51.81% 269.77% -49.30% -66.34% 86.83%
EPS Growth
300.00% -40.00% -127.78% 0.00% -200.00% -58.33% 500.00% -75.00% -83.33% 100.00%
Operating Cash Flow Growth
13.23% -2.18% 5.87% -9.37% -1.00% -9.00% -23.87% -4.05% 5.93% -1.58%
Free Cash Flow Firm Growth
-88.85% -45.40% 73.77% 237.84% 202.67% 164.20% 127.14% 49.54% 17.31% 11.53%
Invested Capital Growth
-1.23% -4.62% -5.88% -8.01% -9.39% -7.82% -3.23% 6.46% 10.36% 14.57%
Revenue Q/Q Growth
2.06% -0.81% -3.47% 8.67% -8.33% 1.63% -0.27% -1.00% -0.71% 0.52%
EBITDA Q/Q Growth
-16.32% -1.17% -5.65% 4.18% -6.24% 2.68% -2.26% -2.04% -3.52% -1.16%
EBIT Q/Q Growth
-170.79% 9.57% -38.16% 63.07% -44.22% 82.89% -17.59% -8.61% -43.62% -14.55%
NOPAT Q/Q Growth
-149.55% 9.57% -38.16% 63.07% -44.22% 82.89% -17.59% -8.61% -43.62% -14.55%
Net Income Q/Q Growth
-13.33% 273.72% -184.36% 319.96% -88.60% -65.91% 552.42% 17.65% -81.58% 161.58%
EPS Q/Q Growth
-33.33% 160.00% -600.00% 200.00% -120.00% -72.22% 1,700.00% 0.00% -91.67% 300.00%
Operating Cash Flow Q/Q Growth
25.89% -13.87% 32.43% -21.14% 8.75% -6.78% 13.36% -13.86% -0.03% -22.01%
Free Cash Flow Firm Q/Q Growth
-76.03% -21.81% -29.79% -15.26% 17.36% 148.87% 155.69% 36.88% 26.61% -5.20%
Invested Capital Q/Q Growth
0.72% 0.12% -1.88% -0.18% -2.73% -1.20% -4.10% -1.68% -1.05% 3.71%
Profitability Metrics
- - - - - - - - - -
EBITDA Margin
48.37% 59.00% 59.22% 60.59% 63.20% 61.79% 61.16% 62.40% 63.07% 64.91%
EBIT Margin
-4.02% 5.80% 5.25% 8.20% 5.46% 8.98% 4.99% 6.04% 6.54% 11.52%
Profit (Net Income) Margin
10.65% 12.55% -7.16% 8.20% 2.12% 17.06% 50.84% 7.77% 6.54% 35.26%
Tax Burden Percent
-264.77% 216.26% -136.41% 100.00% 38.83% 189.98% 1,019.19% 128.73% 100.00% 306.14%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-0.26% 0.51% 0.47% 0.71% 0.47% 0.77% 0.44% 0.53% 0.57% 0.95%
ROIC Less NNEP Spread (ROIC-NNEP)
0.33% 0.81% -0.08% 0.71% 0.34% 1.12% 2.43% 0.61% 0.57% 2.03%
Return on Net Nonoperating Assets (RNNOA)
0.36% 0.84% -0.08% 0.76% 0.35% 1.13% 2.42% 0.61% 0.57% 1.95%
Return on Equity (ROE)
0.11% 1.35% 0.39% 1.48% 0.82% 1.91% 2.85% 1.14% 1.14% 2.90%
Cash Return on Invested Capital (CROIC)
1.59% 5.28% 6.68% 8.95% 10.40% 8.71% 3.92% -5.42% -8.82% -12.33%
Operating Return on Assets (OROA)
-0.35% 0.49% 0.45% 0.69% 0.45% 0.75% 0.42% 0.51% 0.55% 0.91%
Return on Assets (ROA)
0.93% 1.07% -0.61% 0.69% 0.18% 1.42% 4.27% 0.66% 0.55% 2.78%
Return on Common Equity (ROCE)
0.09% 1.14% 0.33% 1.25% 0.70% 1.63% 2.44% 0.98% 0.98% 2.50%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.79% 1.03% 3.80% 0.00% 3.77% 4.56% 2.92% 0.00% 3.64%
Net Operating Profit after Tax (NOPAT)
-0.78 1.57 1.43 2.31 1.42 2.54 1.39 1.69 1.85 3.28
NOPAT Margin
-2.82% 5.80% 5.25% 8.20% 5.46% 8.98% 4.99% 6.04% 6.54% 11.52%
Net Nonoperating Expense Percent (NNEP)
-0.59% -0.29% 0.55% 0.00% 0.13% -0.35% -1.99% -0.08% 0.00% -1.08%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
104.02% 94.20% 94.75% 91.80% 94.54% 91.02% 95.01% 93.96% 93.46% 88.48%
Earnings before Interest and Taxes (EBIT)
-1.11 1.57 1.43 2.31 1.42 2.54 1.39 1.69 1.85 3.28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
13 16 16 17 16 18 17 17 18 18
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
1.12 1.39 1.24 1.12 1.30 1.01 1.01 0.99 0.93 0.83
Price to Tangible Book Value (P/TBV)
1.64 2.01 1.76 1.58 1.82 1.38 1.37 1.39 1.28 1.14
Price to Revenue (P/Rev)
4.68 5.99 5.42 5.08 6.01 4.80 4.87 4.73 4.62 4.57
Price to Earnings (P/E)
635.91 0.00 0.00 37.61 44.77 33.73 26.21 47.19 38.84 28.46
Dividend Yield
10.88% 8.48% 9.25% 9.82% 8.32% 10.21% 10.04% 10.29% 10.64% 11.47%
Earnings Yield
0.16% 0.00% 0.00% 2.66% 2.23% 2.96% 3.82% 2.12% 2.57% 3.51%
Enterprise Value to Invested Capital (EV/IC)
1.04 1.14 1.09 1.04 1.12 0.99 0.99 0.98 0.95 0.91
Enterprise Value to Revenue (EV/Rev)
11.34 12.60 11.82 11.47 12.38 11.00 11.11 11.47 11.43 11.88
Enterprise Value to EBITDA (EV/EBITDA)
19.97 20.83 19.32 18.61 19.92 17.72 17.67 17.89 17.51 18.21
Enterprise Value to EBIT (EV/EBIT)
297.16 202.97 168.31 165.24 193.58 165.58 152.47 121.65 96.67 114.82
Enterprise Value to NOPAT (EV/NOPAT)
297.16 202.97 168.31 165.24 193.58 165.58 152.47 121.65 96.67 78.37
Enterprise Value to Operating Cash Flow (EV/OCF)
17.83 20.20 19.08 18.92 19.92 18.02 17.80 17.07 16.73 16.41
Enterprise Value to Free Cash Flow (EV/FCFF)
65.04 21.18 15.79 11.17 10.24 10.89 24.77 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
1.16 1.11 1.06 1.03 1.01 0.97 0.97 1.10 1.07 1.04
Long-Term Debt to Equity
0.03 0.03 0.03 0.04 0.04 0.09 0.09 0.09 0.09 0.09
Financial Leverage
1.08 1.04 1.02 1.07 1.04 1.01 1.00 1.00 0.99 0.96
Leverage Ratio
2.17 2.12 2.10 2.15 2.12 2.09 2.08 2.07 2.06 2.05
Compound Leverage Factor
2.17 2.12 2.10 2.15 2.12 2.09 2.08 2.07 2.06 2.05
Debt to Total Capital
53.75% 52.69% 51.48% 50.85% 50.22% 49.36% 49.36% 52.41% 51.68% 51.04%
Short-Term Debt to Total Capital
52.55% 51.48% 50.25% 48.74% 48.09% 44.82% 44.85% 48.07% 47.38% 46.77%
Long-Term Debt to Total Capital
1.20% 1.21% 1.23% 2.11% 2.13% 4.54% 4.51% 4.34% 4.29% 4.27%
Preferred Equity to Total Capital
6.24% 6.28% 6.29% 6.17% 6.16% 5.99% 5.92% 5.68% 5.58% 5.52%
Noncontrolling Interests to Total Capital
1.81% 1.85% 1.84% 1.82% 1.83% 1.77% 1.72% 1.19% 1.20% 1.17%
Common Equity to Total Capital
38.20% 39.18% 40.39% 41.16% 41.79% 42.88% 43.00% 40.72% 41.54% 42.27%
Debt to EBITDA
10.33 9.59 9.14 9.07 8.93 8.85 8.83 9.56 9.49 10.18
Net Debt to EBITDA
10.18 9.44 9.01 8.95 8.82 8.60 8.56 9.25 9.19 9.87
Long-Term Debt to EBITDA
0.23 0.22 0.22 0.38 0.38 0.81 0.81 0.79 0.79 0.85
Debt to NOPAT
153.73 93.42 79.61 80.56 86.80 82.68 76.21 65.02 52.41 43.81
Net Debt to NOPAT
151.43 92.01 78.48 79.45 85.75 80.34 73.84 62.90 50.73 42.47
Long-Term Debt to NOPAT
3.43 2.15 1.90 3.35 3.68 7.61 6.96 5.39 4.35 3.66
Noncontrolling Interest Sharing Ratio
16.69% 16.20% 15.88% 15.32% 15.00% 14.48% 14.48% 14.07% 14.05% 13.93%
Liquidity Ratios
- - - - - - - - - -
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
14 59 76 108 128 109 44 -78 -124 -169
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
1.88 8.20 10.85 15.69 18.26 15.16 5.16 -9.48 -15.41 -24.31
Operating Cash Flow to Interest Expense
2.71 2.25 2.71 2.07 2.60 2.32 2.11 1.91 2.27 2.63
Operating Cash Flow Less CapEx to Interest Expense
2.71 2.25 2.71 2.07 2.60 2.32 2.11 1.91 2.27 2.63
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.09 0.09 0.09 0.08 0.08 0.08 0.08 0.09 0.08 0.08
Fixed Asset Turnover
0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.10
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
1,202 1,193 1,192 1,215 1,217 1,251 1,267 1,321 1,343 1,357
Invested Capital Turnover
0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.08
Increase / (Decrease) in Invested Capital
-15 -58 -74 -106 -126 -106 -42 80 126 173
Enterprise Value (EV)
1,249 1,366 1,297 1,267 1,363 1,237 1,251 1,295 1,280 1,239
Market Capitalization
516 650 596 561 662 540 548 535 517 477
Book Value per Share
$6.87 $7.13 $7.34 $7.63 $7.76 $8.18 $8.31 $8.21 $8.52 $8.76
Tangible Book Value per Share
$4.71 $4.94 $5.17 $5.42 $5.55 $5.98 $6.09 $5.85 $6.17 $6.41
Total Capital
1,202 1,193 1,192 1,215 1,217 1,251 1,267 1,321 1,343 1,357
Total Debt
646 629 614 618 611 618 625 692 694 693
Total Long-Term Debt
14 14 15 26 26 57 57 57 58 58
Net Debt
636 619 605 609 604 600 606 670 672 672
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Nonoperating Expense (NNE)
-3.72 -1.82 3.38 0.00 0.87 -2.29 -13 -0.49 0.00 -6.75
Net Nonoperating Obligations (NNO)
646 629 614 618 611 618 625 692 694 693
Total Depreciation and Amortization (D&A)
14 14 15 15 15 15 16 16 16 15
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.02 $0.03 ($0.05) $0.01 ($0.01) $0.05 $0.18 $0.01 $0.01 $0.12
Adjusted Weighted Average Basic Shares Outstanding
65.94M 65.74M 65.59M 65.57M 65.55M 65.57M 65.54M 65.53M 65.46M 65.52M
Adjusted Diluted Earnings per Share
$0.02 $0.03 ($0.05) $0.01 ($0.01) $0.05 $0.18 $0.01 $0.01 $0.12
Adjusted Weighted Average Diluted Shares Outstanding
65.94M 65.74M 65.59M 65.57M 65.55M 65.57M 65.54M 65.53M 65.46M 65.52M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
66.87M 66.80M 65.59M 65.59M 65.57M 65.56M 65.56M 65.53M 65.53M 65.52M
Normalized Net Operating Profit after Tax (NOPAT)
-0.67 1.10 1.00 1.62 0.99 1.78 0.98 1.21 1.37 2.37
Normalized NOPAT Margin
-2.42% 4.06% 3.68% 5.74% 3.82% 6.28% 3.50% 4.33% 4.86% 8.34%
Pre Tax Income Margin
-4.02% 5.80% 5.25% 8.20% 5.46% 8.98% 4.99% 6.04% 6.54% 11.52%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-0.15 0.22 0.20 0.34 0.20 0.35 0.16 0.20 0.23 0.47
NOPAT to Interest Expense
-0.10 0.22 0.20 0.34 0.20 0.35 0.16 0.20 0.23 0.47
EBIT Less CapEx to Interest Expense
-0.15 0.22 0.20 0.34 0.20 0.35 0.16 0.20 0.23 0.47
NOPAT Less CapEx to Interest Expense
-0.10 0.22 0.20 0.34 0.20 0.35 0.16 0.20 0.23 0.47
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
981.62% 1,519.49% 1,136.55% 297.57% 298.37% 280.81% 228.49% 360.20% 321.27% 268.92%
Augmented Payout Ratio
981.62% 1,519.49% 1,136.55% 297.57% 298.37% 280.81% 228.49% 360.20% 321.27% 268.92%

Frequently Asked Questions About Global Medical REIT's Financials

When does Global Medical REIT's financial year end?

According to the most recent income statement we have on file, Global Medical REIT's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Global Medical REIT's net income changed over the last 2 years?

Global Medical REIT's net income appears to be on a downward trend, with a most recent value of $6.69 million in 2024, falling from $20.00 million in 2022. The previous period was $21.73 million in 2023. See where experts think Global Medical REIT is headed by visiting Global Medical REIT's forecast page.

How has Global Medical REIT revenue changed over the last 2 years?

Over the last 2 years, Global Medical REIT's total revenue changed from $112.05 million in 2022 to $110.09 million in 2024, a change of -1.8%.

How much debt does Global Medical REIT have?

Global Medical REIT's total liabilities were at $700.57 million at the end of 2024, a 5.8% increase from 2023, and a 5.9% decrease since 2022.

How much cash does Global Medical REIT have?

In the past 2 years, Global Medical REIT's cash and equivalents has ranged from $1.28 million in 2023 to $6.82 million in 2024, and is currently $6.82 million as of their latest financial filing in 2024.

How has Global Medical REIT's book value per share changed over the last 2 years?

Over the last 2 years, Global Medical REIT's book value per share changed from 8.52 in 2022 to 6.87 in 2024, a change of -19.3%.



This page (NYSE:GMRE) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners